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We read with interest the analysis of the merged Thrombolysis In
Myocardial Infarction (TIMI) database showing an increased risk
of myocardial infarction (MI) but not death in patients with acute
coronary syndromes (ACS) who were previously on aspirin therapy
(1). The authors conclude that previous aspirin use was “a marker
as opposed to a pathophysiologic factor related to an increased
risk” for ACS. They explain that “although prior aspirin use was
associated with an increase in the risk of recurrent MI and the
composite end point. . .this may be attributable to confounders
that cannot be corrected for, aspirin resistance, or both.”
In their discussion, the authors point to meta-analysis reports of
4 ACS trials, PURSUIT (Platelet glycoprotein IIb/IIIa in Unsta-
ble angina: Receptor Suppression Using Integrilin Therapy) (2),
TIMI 11B (3), ESSENCE (Efficacy and Safety of Subcutaneous
Enoxaparin in Non-Q wave Coronary Events), and PRISM-
PLUS (Platelet Receptor Inhibition in Ischemic Syndrome Man-
agement in Patients Limited by Unstable Signs and Symptoms)
(4), which all showed a similar increase in recurrent MI and
composite endpoints but lack of increased mortality in the groups
previously taking aspirin.
Unfortunately, the authors did not emphasize the unique
presentations of previous aspirin users and their differential re-
sponses to antithrombotic and antiplatelet therapy that were
common in all 4 reports. We believe that such analysis make a
pathophysiologic link much more plausible.
First, in all 4 trials (as well as in the current report), participants
who were previously taking aspirin were significantly less likely to
present with an MI than those not taking aspirin. Conversely,
during their hospital course and after discharge, previous aspirin
users collectively had a significantly higher number of recurrent
MIs than those not previously on aspirin therapy. This “paradox-
ical” effect of previous aspirin use may also explain why some
reports have shown worse outcomes in previous aspirin users,
whereas others have shown better outcomes or no difference (5–7).
The most impressive evidence that there is a pathophysiologic
effect of previous aspirin use, however, is the finding in all 4 studies
that the benefit of low molecular weight heparin or the addition of
platelet glycoprotein IIb/IIIa inhibitors to unfractionated heparin
(UFH) is noted only in patients previously using aspirin. This
effect is so strong that it has been argued (8) that the beneficial
effect of enoxaparin in the TIMI 11B trial relied on the fact that
84% of the patients enrolled were previous aspirin users, and so
were responsive to enoxaparin over UFH. If the majority of
patients were not previously taking aspirin, the study findings may
have been negative.
Although previous aspirin users in these 4 trials had more
comorbidities than the group not previously using aspirin, these
demographic differences were not present within the previous
aspirin user group, and so risk factors alone cannot explain the
heterogeneous response to antithrombin and antiplatelet ther-
apies compared with UFH; nor can they explain why the differ-ential response does not exist in the group not previously using
aspirin (8).
We believe that these data highly suggest that patients with
“aspirin failure” have a pathophysiologically distinct thrombus with
unique properties. Furthermore, we believe that the phenomenon
of aspirin failure should be called “clinical aspirin resistance” (to
distinguish it from “laboratory aspirin resistance”) because it exists
clinically, but, at present, there is no reliable method for measuring
it in the laboratory (9).
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Reply
Although Dr. Lancaster and colleagues claim that we “did not
emphasize the unique presentations of previous aspirin users,” we
actually did—in the abstract of our paper: “Prior aspirin use was
associated with less severe types of ACS at presentation (e.g.,
unstable angina non–ST-segment elevation MI ST-segment
elevation MI) than their nonaspirin user counterparts (p 
0.0001)” (1). We then devote an entire paragraph in the Discus-
sion section to this, complete with a list of 7 references: “Our study
also found that prior aspirin use was associated with less severe
forms of ACS at the time of presentation, a finding consistent with
those of nearly all of the previously mentioned studies (9–11,33)
and others as well (36–38).” We are not sure how we could have
emphasized it more clearly.
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weight heparin or the addition of platelet glycoprotein IIb/IIIa
inhibitors to unfractionated heparin (UFH) is noted only in
patients previously using aspirin.” The data do not support this.
Specifically, the interaction p value for low molecular weight
heparin versus UFH in the TIMI (Thrombolysis In Myocardial
Infarction) 11B trial was p  0.376 (2), and for platelet glyco-
protein IIb/IIIa inhibition versus placebo in the PURSUIT trial, it
was p 0.534 (3) Indeed, the PURSUIT investigators state clearly
in the abstract of their paper: “In a multivariable model, eptifi-
batide did not [emphasis added] have a different treatment effect in
prior aspirin users compared with nonusers (p  0.534).” As such,
the rest of their argument of the “differential response” does not
hold because there is not a differential response.
But even if a marker did identify a population with a differential
response, that would not necessarily implicate it in the pathophys-
iology of the benefit. A case in point is troponin. In TACTICS–
TIMI 18, we prospectively demonstrated that an early invasive
strategy provides particular benefit in troponin-positive patients
(4). This does not mean that the invasive strategy had a myocardial
necrosis-sparing effect in this population.
Thus, we do not follow any of the authors’ arguments regarding
aspirin resistance. We believe that our analysis of 16 trials strongly
supports the fact that previous aspirin use is a marker of high risk,
but further research is needed with other more specific markers to
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